Revelation Biosciences (NASDAQ:REVB) Posts Earnings Results

Revelation Biosciences (NASDAQ:REVB) announced its earnings results on Friday. The company reported ($0.87) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.01, FiscalAI reports.

Revelation Biosciences Price Performance

NASDAQ:REVB traded up $0.02 during mid-day trading on Friday, hitting $1.14. 25,572 shares of the company’s stock were exchanged, compared to its average volume of 42,163. The company has a market cap of $4.46 million, a PE ratio of -0.09 and a beta of -0.15. Revelation Biosciences has a one year low of $0.88 and a one year high of $11.72. The business has a fifty day moving average price of $1.04 and a 200 day moving average price of $1.27.

Analyst Ratings Changes

Separately, Weiss Ratings cut Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a research note on Tuesday, July 28th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Revelation Biosciences currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Revelation Biosciences

An institutional investor recently raised its stake in Revelation Biosciences stock. Armistice Capital LLC increased its stake in Revelation Biosciences, Inc. (NASDAQ:REVB) by 442.8% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 434,272 shares of the company’s stock after buying an additional 354,272 shares during the period. Armistice Capital LLC owned 6.29% of Revelation Biosciences worth $347,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 12.80% of the company’s stock.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.